Novel Isoquinolinone-Derived Inhibitors of Poly(ADP-ribose) Polymerase-1: Pharmacological Characterization and Neuroprotective Effects in an in Vitro Model of Cerebral Ischemia
- 1 June 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (3) , 943-949
- https://doi.org/10.1124/jpet.103.048934
Abstract
The diarylheptanoid 7-(4′-hydroxy-3′-methoxyphenyl)-1-phenylhept-4-en-3-one (HMP) is a naturally occurring phytochemical found in lesser galangal (Alpinia officinarum). In the present study, we have demonstrated the anti-inflammatory properties of this compound on mouse macrophage cell line (RAW 264.7) and human peripheral blood mononuclear cells (PBMCs) in vitro. Treatment of RAW 264.7 cells with HMP (6.25–25 μM) significantly inhibited lipopolysaccharide (LPS)-stimulated nitric oxide (NO) production. This compound also inhibited the release of LPS-induced proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) from human PB-MCs in vitro. In addition, Western blotting and reverse transcription-polymerase chain reaction analysis demonstrated that HMP decreased LPS-induced inducible nitric-oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein and mRNA expression in RAW 264.7 cells. Furthermore, HMP treatment also reduced nuclear factor-κB (NF-κB) DNA binding induced by LPS in RAW 264.7 cells. To elucidate the molecular mechanism for inhibition of proinflammatory mediators by HMP (25 μM), we have studied the effect of HMP on LPS-induced p38 and p44/42 mitogen-activated protein kinase (MAPK). We observed that the phosphorylation of p44/42 MAPK in LPS-stimulated RAW 264.7 cells was markedly inhibited by HMP, whereas activation of p38 MAPK was not affected. These results suggested that HMP from lesser galangal suppressed the LPS-induced production of NO, IL-1β, and TNF-α and expression of iNOS and COX-2 gene expression by inhibiting NF-κB activation and phosphorylation of p44/42 MAPK.This publication has 38 references indexed in Scilit:
- Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity: Design, Synthesis, and X-ray Cocrystal StructureJournal of Medicinal Chemistry, 2002
- Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisitedTrends in Pharmacological Sciences, 2002
- Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure−Activity Relationship AnalysisJournal of Medicinal Chemistry, 2001
- Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functionsBiochemical Journal, 1999
- Immunological determination and size characterization of poly(ADP-ribose) synthesized in vitro and in vivoBiochimica et Biophysica Acta (BBA) - General Subjects, 1999
- Effects of inhibitors of the activity of poly (ADP‐ribose) synthetase on the liver injury caused by ischaemia‐reperfusion: a comparison with radical scavengersBritish Journal of Pharmacology, 1998
- Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)PolymeraseJournal of Cerebral Blood Flow & Metabolism, 1997
- Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemiaNature Medicine, 1997
- Structure and function of poly(ADP-ribose) polymeraseMolecular and Cellular Biochemistry, 1994
- Poly(ADP‐ribose) polymerase: Early involvement in glutamate‐induced neurotoxicity in cultured cerebellar granule cellsJournal of Neuroscience Research, 1994